Romano Quoted in Modern Healthcare About the Need to Change Stark Law and Anti-Kickback Statute Regulations
22 June 2020
Of Counsel Don Romano was quoted in the Modern Healthcare article, “Stark, anti-kickback laws can’t come soon enough, experts say,” which looked at the need for change to Stark Law and Anti-Kickback Statute regulations amid the pandemic. But the pandemic may also delay those rule changes.
COVID-19 could also affect how CMS and OIG finalize the proposed rules because the agencies are considering alternative versions of some proposed policies. “Some of those (policies) may be more liberal than others,” Romano said. “It’s possible that the COVID crisis is going to inform which of those choices the agencies settle on.”
For example, the in-office ancillary services exception is the most important exception under the Stark Law because it requires that a service be performed in a specific place called “the same building” or “centralized building.”
“With the move toward more telehealth … CMS might get to the point where it has a more liberal interpretation of the location requirement, but it can only bend it around the edges because that’s a statutory requirement,” Romano said.
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”